Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 09:48:17 2024-05-13 am EDT			5-day change	1st Jan Change
92.43 ^EUR	+2.05%		+1.24%	+2.97%

03:21pm	France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update	DJ
03:03pm	Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment	MT

Sanofi appoints Smith & Nephew CFO Nesmes to board

February 23, 2024 at 05:22 am EST

Sanofi SA - Paris-based pharmaceutical company - Appoints Anne-Francoise Nesmes, chief financial officer of Watford, England-based medical devices maker Smith & Nephew PLC, to board as an independent non-executive director, with effect from April 30.

Current Sanofi stock price: EUR88.86, up 0.1% on Friday morning in Paris

12-month change: down 1.4%

Current Smith & Nephew stock price: 1,132.16 pence each, down 0.5% on Friday morning in London

12-month change: down 7.4%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	SMITH & NEPHEW PLC	1,011 GBX	+0.65%	+1.12%	10.96B
	SANOFI	92.43 EUR	+2.05%	+1.24%	127B

Latest news about Sanofi

France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update	09:21am	DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment	09:03am	MT
Sanofi to Invest $1.08 Billion Into Three French Drug Manufacturing Sites	09:01am	MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug	08:58am	MT
Sanofi to Invest $1.08 Billion Into 3 French Drug Manufacturing Sites	07:56am	MT
SANOFI : Sell rating from Deutsche Bank	07:10am	ZD
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal	06:38am	DJ
SANOFI : Berenberg maintains a Buy rating	06:29am	ZD
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	06:25am	DJ
France Secures Billions at Foreign Investment Summit	05:55am	DJ
CAC40: stable at the start of a week packed with indicators	05:11am	CF
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review	04:53am	MT
Sanofi to Spend $1.08 Billion to Boost Drug Production in France	04:23am	DJ
Sanofi invests 1.1 billion euros in France	02:54am	CF
Sanofi Plans EUR1 Billion Investments in France	01:50am	MT
Sanofi pledges new 1 bln euros worth of investments in French production sites	01:09am	RE
News Highlights : Top Company News of the Day - Friday at 7 PM ET	May. 10	DJ
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	May. 10	DJ
US Equity Markets Close Mixed Friday After Consumer Sentiment Falls	May. 10	MT
Sector Update: Health Care Stocks Higher Late Afternoon	May. 10	MT
News Highlights : Top Company News of the Day - Friday at 3 PM ET	May. 10	DJ
Novavax shares soar on license deal with Sanofi	May. 10	RE
Sector Update: Health Care Stocks Advance Friday Afternoon	May. 10	MT
Wall St mixed but headed for weekly gains ahead of inflation data	May. 10	RE
Top MIdday Gainers	May. 10	MT

Chart Sanofi

Duration

Period

More charts

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-05-12 - Ex-dividend day for final dividend

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

94.33 EUR

Average target price

108.1 EUR

Spread / Average Target

+14.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+2.97%	127B
ELI LILLY AND COMPANY	+30.55%	684B
NOVO NORDISK A/S	+29.84%	568B
JOHNSON & JOHNSON	-4.15%	361B
MERCK & CO., INC.	+18.53%	329B
ABBVIE INC.	+3.90%	284B
ASTRAZENECA PLC	+15.72%	240B
NOVARTIS AG	+9.18%	208B
ROCHE HOLDING AG	-7.36%	200B
AMGEN INC.	+7.77%	166B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Sanofi appoints Smith & Nephew CFO Nesmes to board

Stocks mentioned in the article

EPS Revisions